Teon Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Phase 1
Terminated
- Conditions
- CancerAdvanced CancerAdvanced Solid TumorOncology
- Interventions
- Drug: A PD-1 inhibitor
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Teon Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05525455
- Locations
- 🇺🇸
Teon Investigational Site, Fairfax, Virginia, United States
News
No news found